Business Wire

FINARO

1.12.2021 17:07:05 CET | Business Wire | Pressemeddelelse

Del
Den globale betalingsudbyder, Credorax, skifter navn til ‘Finaro’

En af de førende betalingsudbydere, indløser og bank, Credorax, har i dag annonceret dens nye virksomhedsidentitet, Finaro .

Med fokus på kerneforretningen og med at skabe tekniske løsninger til at forenkle betalinger og gøre en ekstra indsats for dens kunder, styrker Finaro global e-handel, ved at levere den ideelle løsning til virksomheder på tværs af landegrænser, med dens banebrydende teknologi og kundeorienteret support.

Nyhederne om navneskiftet støtter godt op om et stærkt 2021, med Finaros imponerende 40% årlig vækst. Virksomheden er grundlagt i 2009 og har på nuværende tidspunkt mere end 350 ansatte. De er baseret i Israel og Malta men har også tilstedeværelse på det kinesiske fastland, Hong Kong, USA og flere steder i Europa.

Credorax har allerede bevist sig som en betalingsudbyder der fremmer sine erhvervskunders vækst, og med den globale fintech-sektor der forventes at stige til $190bn i 2026 , skaber denne hastigt stigende kurve det perfekte miljø for Finaros nye brand til at etablere sig som en stærk spiller i markedet. Denne vækst i fintech har set salg på tværs af grænser tage mere end en fjerdedel af hele e-handelsmarkedspladsen i Europa, hvilket fremhæver betydningen af en udbyder der kan gøre komplekse betalingsløsninger enkle.

Finaro servicerer i dag mere end 5.000 erhvervskunder overalt i verden og indenfor en bred vifte af brancher, inklusiv detail, digitale produkter og ydelser, rejsebranchen, hotel og transportbranchen. Kiwi.com, Air Baltic, Wolt, Payrexx, Revolut, Go2Mobile og Hero Gaming er blandt dens kunder og på tværs af alle kategorier er tendensen den samme: alle kunder arbejder inden for et meget konkurrerende marked, og de skal derfor skabe perfekte kundeoplevelser. Finaro er ledet af et team af betalingseksperter og problemløsere, der er fast besluttede på at absorbere den enorme kompleksitet af betalinger og levere enkelhed, så kunder er frie til at forfølge deres ambition, velvidende at de er dækket ind på deres betalinger.

“Vores firmas succes har altid været bygget på vores interne, banebrydende full stack-platform, såvel som stærke kunderelationer og konstant produktinnovation. Vores passionerede team af problemløsere med en positiv tilgangsvinkel, gør os i stand til at skabe intelligente og enkle betalingsløsninger til vores kunder, siger Igal Rotem, administrerende direktør for Finaro.

“Vores udvikling fra Credorax til Finaro afspejler den udvikling vores virksomhed har gennem gået, siden vi sluttede os til betalingsverden for 15 år siden, og vores navneændring er det næste skridt i vores vækst som en virksomhed og på vores sti mod at realisere vores vision om handel uden bindinger . Jeg er utrolig stolt over at løfte sløret for vores nye identitet som Finaro ,” fortsætter Igal.

“Vi kom ind i denne branche med et friskt syn på tingene, fordi vi så forhindringer som skulle overvindes, og det er hvad vi har gjort lige siden,” kommenterede Moshe Selfin, Cheif Technical Officer for Finaro. “ Vi var pionerer med en innovativ tilgangsmåde til betalinger, som udreder selv de vanskeligste problemer i betalingsområdet, hvilket baner vejen for nye og spændende muligheder og giver vores erhvervskunder en meningsfuld og konkurrencedygtig fordel.”

“Branding er meget mere end blot farver, logoer og slogans - det handler om essensen af vores virksomhed og hvordan vi præsenteres til verden udadtil. Da vi udviklede vores nye varemærke Finaro, krystaliserede vi vores essens, og det var altafgørende, at demonstrere vores identitet som en virksomhed der tager sig af sine kunder og kan levere det enestående,” forklarer Achiya Fried, Chief Commercial Officer for Finaro , “Vi gør en ekstra indsats i fleksibilitet, og vi skaber løsninger sammen med vores kunder, ved at levere banebrydende, flerdimensionelle betalingsløsninger der udreder kompleksiteten ved betalinger. Vores nye varemærke, Finaro , afspejler lige præcis dette."

###ENDS###

Om Finaro

Finaro er en global betalingsudbyder der på tværs af grænser styrker international handel gennem fremragende enkle betalinger. Vores dedikerede team, enestående teknologiske formåen, produktinnovation og kundefokuserede tilgang, gør os i stand til at forenkle kompleksitet og skabe flerdimensionelle løsninger der medfører vækst og giver ro i sindet for vores erhvervsdrivende. For at lære mere kan du besøge www.finaro.com .

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye